CONTEXT: The contribution of reproductive hormones to mood has been the focus of considerable research. Results from clinical and epidemiological studies have been inconsistent. It remains unclear whether alterations in serum hormone levels across the menopausal transition are linked to depressive symptoms. OBJECTIVES: To evaluate the relationship between serum hormone levels and high depressive symptoms and whether hormone levels or their change might explain the association of menopausal status with depressive symptoms previously reported in a national sample of midlife women. DESIGN: A longitudinal, community-based, multisite study of menopause. Data were collected at baseline and annually from December 1995 to January 2008 on a range of factors. Early follicular phase serum samples were assayed for levels of estradiol, follicle-stimulating hormone, testosterone, and dehydroepiandrosterone sulfate. SETTING: Seven communities nationwide. PARTICIPANTS: A community-based sample of 3302 multiethnic women, aged 42 to 52 years, still menstruating and not using exogenous reproductive hormones. Main Outcome Measure Depressive symptoms assessed with the Center for Epidemiological Studies Depression Scale (CES-D). The primary outcome was a CES-D score of 16 or higher. RESULTS: In multivariable random-effects logistic regression models, log-transformed testosterone level was significantly positively associated with higher odds of a CES-D score of 16 or higher (odds ratio = 1.15; 95% confidence interval, 1.01-1.31) across 8 years, and a larger increase in log-transformed testosterone from baseline to each annual visit was significantly associated with increased odds of a CES-D score of 16 or higher (odds ratio = 1.23; 95% confidence interval, 1.04-1.45). Less education, being Hispanic, and vasomotor symptoms, stressful life events, and low social support at each visit were each independently associated with a CES-D score of 16 or higher. No other hormones were associated with a CES-D score of 16 or higher. Being perimenopausal or postmenopausal compared with being premenopausal remained significantly associated with a CES-D score of 16 or higher in all analyses. CONCLUSIONS: Higher testosterone levels may contribute to higher depressive symptoms during the menopausal transition. This association is independent of menopausal status, which remains an independent predictor of higher depressive symptoms.
CONTEXT: The contribution of reproductive hormones to mood has been the focus of considerable research. Results from clinical and epidemiological studies have been inconsistent. It remains unclear whether alterations in serum hormone levels across the menopausal transition are linked to depressive symptoms. OBJECTIVES: To evaluate the relationship between serum hormone levels and high depressive symptoms and whether hormone levels or their change might explain the association of menopausal status with depressive symptoms previously reported in a national sample of midlife women. DESIGN: A longitudinal, community-based, multisite study of menopause. Data were collected at baseline and annually from December 1995 to January 2008 on a range of factors. Early follicular phase serum samples were assayed for levels of estradiol, follicle-stimulating hormone, testosterone, and dehydroepiandrosterone sulfate. SETTING: Seven communities nationwide. PARTICIPANTS: A community-based sample of 3302 multiethnic women, aged 42 to 52 years, still menstruating and not using exogenous reproductive hormones. Main Outcome Measure Depressive symptoms assessed with the Center for Epidemiological Studies Depression Scale (CES-D). The primary outcome was a CES-D score of 16 or higher. RESULTS: In multivariable random-effects logistic regression models, log-transformed testosterone level was significantly positively associated with higher odds of a CES-D score of 16 or higher (odds ratio = 1.15; 95% confidence interval, 1.01-1.31) across 8 years, and a larger increase in log-transformed testosterone from baseline to each annual visit was significantly associated with increased odds of a CES-D score of 16 or higher (odds ratio = 1.23; 95% confidence interval, 1.04-1.45). Less education, being Hispanic, and vasomotor symptoms, stressful life events, and low social support at each visit were each independently associated with a CES-D score of 16 or higher. No other hormones were associated with a CES-D score of 16 or higher. Being perimenopausal or postmenopausal compared with being premenopausal remained significantly associated with a CES-D score of 16 or higher in all analyses. CONCLUSIONS: Higher testosterone levels may contribute to higher depressive symptoms during the menopausal transition. This association is independent of menopausal status, which remains an independent predictor of higher depressive symptoms.
Authors: T J Fabian; M A Dew; B G Pollock; C F Reynolds; B H Mulsant; M A Butters; M D Zmuda; A M Linares; M Trottini; P D Kroboth Journal: Biol Psychiatry Date: 2001-11-15 Impact factor: 13.382
Authors: P J Schmidt; L Nieman; M A Danaceau; M B Tobin; C A Roca; J H Murphy; D R Rubinow Journal: Am J Obstet Gynecol Date: 2000-08 Impact factor: 8.661
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: J Clin Endocrinol Metab Date: 2012-02-16 Impact factor: 5.958
Authors: Catheryne Chiang; Lisa Gallicchio; Howard Zacur; Sue Miller; Jodi A Flaws; Rebecca L Smith Journal: Maturitas Date: 2018-10-23 Impact factor: 4.342
Authors: Wendy K Marsh; Joyce T Bromberger; Sybil L Crawford; Katherine Leung; Howard M Kravitz; John F Randolph; Hadine Joffe; Claudio N Soares Journal: Menopause Date: 2017-12 Impact factor: 2.953
Authors: Joyce T Bromberger; Laura L Schott; Nancy E Avis; Sybil L Crawford; Sioban D Harlow; Hadine Joffe; Howard M Kravitz; Karen A Matthews Journal: Psychol Med Date: 2018-04-06 Impact factor: 7.723
Authors: Peter J Schmidt; Jamie A Luff; Nazli A Haq; Vien H Vanderhoof; Deloris E Koziol; Karim A Calis; David R Rubinow; Lawrence M Nelson Journal: J Clin Endocrinol Metab Date: 2010-11-03 Impact factor: 5.958
Authors: Alicia Colvin; Gale A Richardson; Jill M Cyranowski; Ada Youk; Joyce T Bromberger Journal: Arch Womens Ment Health Date: 2014-06-21 Impact factor: 3.633
Authors: L Raz; L V Hunter; N M Dowling; W Wharton; C E Gleason; M Jayachandran; L Anderson; S Asthana; V M Miller Journal: Climacteric Date: 2015-12-10 Impact factor: 3.005